drug
maribavir
Marketedupdated 3mo agoby Takeda Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(0)
nothing on the calendar yet
Trials studying maribavir
- phase3A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
- —A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea
- phase4Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
- —A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection
- phase1A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants
- phase1A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants
- phase3A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
- phase1A Study of Maribavir Pediatric Formulation in Healthy Adult Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 23, 2026
102 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (7)
- Oct 11, 2043compositionUS 12295940
- Oct 11, 2043compositionUS 12527771
- Nov 18, 2042method-of-use (U-4137)US 12213989
- Nov 18, 2042method-of-use (U-4289)US 12433907
- Nov 18, 2042method-of-use (U-4328)US 12447170
- Jan 4, 2032method-of-use (U-3650)US 11684632
- Oct 27, 2031method-of-use (U-4329)US 12447169
FDA exclusivities (2)
- Nov 23, 2028ODE-388Orphan Drug (7y)2.3y
- Nov 23, 2026NCENew Chemical Entity (5y)102d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 56m ago
Found something off?
comments(0)
5-min edit window · permanent after that